Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Jose Antonio López Martín
Based on 6 articles published since 2010
(Why 6 articles?)

Between 2010 and 2020, J. A. López-Martín wrote the following 6 articles about Melanoma.
+ Citations + Abstracts
1 Guideline Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. 2014

Martín-Algarra, S / Fernández-Figueras, M T / López-Martín, J A / Santos-Briz, A / Arance, A / Lozano, M D / Berrocal, A / Ríos-Martín, J J / Espinosa, E / Rodríguez-Peralto, J L / Anonymous3550772 / Anonymous3560772. ·Medical Oncology Department, Clínica Universidad de Navarra, Avenida de Pio XII, 36, 31008, Pamplona, Spain, smalgarra@unav.es. ·Clin Transl Oncol · Pubmed #24129426.

ABSTRACT: This consensus statement, conceived as a joint initiative of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM), makes diagnostic and treatment recommendations for the management of patients with advanced or metastatic melanoma based on the current scientific evidence on biomarker use. This document thus provides an opportunity to improve healthcare efficiency and resource use, which will benefit these patients. Based on the data available so far, this expert group recommends routinely testing patients with metastatic melanoma for BRAF mutation status, as the result affects the subsequent therapeutic management of these patients. The analysis of genetic alterations in KIT may be reasonable in patients with primary tumours in acral or mucosal sites or on chronically sun-exposed skin, in an advanced condition, but not in patients with other types of melanomas. This panel believes that testing for other genetic alterations, such as NRAS mutation status in patients not carrying BRAF mutations, GNAQ/GNA11 mutational analysis or genetic alterations in PTEN, is not currently indicated as routine clinical practice, because the results do not influence treatment planning in these patients at the present time. Other important issues addressed in this document are the organisational requirements and quality controls needed for proper testing of these biomarkers, and the legal implications to be borne in mind.

2 Review Advances in cutaneous melanoma. 2012

Espinosa, Enrique / Berrocal, Alfonso / López Martín, José Antonio / González Cao, María / Cerezuela, Pablo / Mayordomo, José Ignacio / Martín Algarra, Salvador / Anonymous810725. ·Service of Oncology, Hospital La Paz, Madrid, Spain. eespinosa00@hotmail.com ·Clin Transl Oncol · Pubmed #22551537.

ABSTRACT: After several decades of slow progress in the field of melanoma, significant advances have been reported in recent years. These include a better understanding of the molecular biology of the tumour, a new staging classification system, insights into the patterns of relapse in early stage, and new drugs for the treatment of advanced disease. Ipilimumab and vemurafenib have just been approved and provide a survival benefit in stage IV. Both compounds are under evaluation in the adjuvant setting, where interferon remains the only drug with proven efficacy. Further investigation is required to treat patients with primary or secondary resistance to new drugs.

3 Clinical Trial Safety of vemurafenib in patients with BRAF 2016

Arance, A M / Berrocal, A / Lopez-Martin, J A / de la Cruz-Merino, L / Soriano, V / Martín Algarra, S / Alonso, L / Cerezuela, P / La Orden, B / Espinosa, E. ·Hospital Clínic and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. AMARANCE@clinic.ub.es. · Hospital General Universitario de Valencia, Valencia, Spain. · Hospital Universitario 12 de Octubre, Madrid, Spain. · Hospital Univ. Virgen de la Macarena de Sevilla, Seville, Spain. · Instituto Valenciano de Oncología, Valencia, Spain. · Clínica Universidad de Navarra, Navarra, Spain. · Hospital Clínico de Málaga, Malaga, Spain. · Hospital Universitario Santa Lucía de Cartagena, Cartagena, Spain. · Roche Farma, Madrid, Spain. · Hospital Universitario La Paz, Madrid, Spain. ·Clin Transl Oncol · Pubmed #26983408.

ABSTRACT: OBJECTIVES: Vemurafenib tolerability was assessed in a large, open-label, multicentre study in patients with BRAF METHODS: Patients with previously treated or treatment-naive, unresectable stage IIIC or stage IV, BRAF RESULTS: 301 Spanish patients were included, 70 % with M1c disease, 22 % with brain metastases and 51 % with prior systemic therapy for metastatic disease. Most frequent adverse events included fatigue (48 %), arthralgia (45 %), rash (41 %), photosensitivity (34 %) and skin neoplasms (21 %). Grade 3/4 adverse events occurred in 156 patients (52 %), including cutaneous squamous cell carcinoma (including keratoacanthoma; 16 %), fatigue (6 %) and arthralgia (5 %). The ORR was 28 % (95 % CI 23-34 %). Responses occurred in patients with brain metastases (18 %), elevated baseline lactate dehydrogenase (19 %) and poor performance status (15 %), and elderly patients (22 %). Median PFS was 5.8 (95 % CI 5.0-6.4) months; median OS was 10.5 (95 % CI 9.5-13.5) months. CONCLUSION: Our results for Spanish patients in the vemurafenib safety study indicate similar efficacy and a comparable safety profile in Spanish patients with no new safety signals compared with the overall population. Clinical benefit was demonstrated in poor-prognosis patients and in those with favourable baseline characteristics, suggesting that poor-prognosis patients may also benefit from vemurafenib treatment.

4 Article Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study. 2017

Martín Algarra, Salvador / Soriano, Virtudes / Fernández-Morales, Luis / Berciano-Guerrero, Miguel-Ángel / Mujika, Karmele / Manzano, José Luis / Puértolas Hernández, Teresa / Soria, Ainara / Rodríguez-Abreu, Delvys / Espinosa Arranz, Enrique / Medina Martínez, Javier / Márquez-Rodas, Ivan / Rubió-Casadevall, Jordi / Ortega, María Eugenia / Jurado García, José Miguel / Lecumberri Biurrun, María José / Palacio, Isabel / Rodríguez de la Borbolla Artacho, María / Altozano, Javier Pérez / Castellón Rubio, Victoria Eugenia / García, Almudena / Luna, Pablo / Ballesteros, Anabel / Fernández, Ovidio / López Martín, Jose Antonio / Berrocal, Alfonso / Arance, Ana. ·Medical Oncology, Clínica Universidad de Navarra, Pamplona. · Instituto Valenciano de Oncología, Valencia. · Medical Oncology, Parc Taulí Sabadell Hospital Universitario, Sabadell. · Oncología Intercentros, Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV) and Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga. · Onkologikoa, Instituto Oncológico de Kutxa, San Sebastian. · Instituto Catalán de Oncología, ICO-Badalona, Hospital Germans Trías I Pujol, Barcelona. · Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza. · Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid. · Medical Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Las Palmas de Gran Canaria. · Medical Oncology, Hospital Universitario La Paz, Madrid. · Medical Oncology, Hospital Virgen de la Salud, Toledo. · Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid. · Instituto Catalán de Oncología Girona, Girona. · Medical Oncology, Hospital Universitario Arnau de Vilanova, Lleida. · Medical Oncology, Hospital Universitario San Cecilio, Granada. · Medical Oncology, Complejo Hospitalario de Navarra, Pamplona. · Medical Oncology, Hospital Universitario Central de Asturias, Oviedo. · Medical Oncology, Hospital Universitario Nuestra Señora de Valme, Sevilla. · Medical Oncology, Hospital General Universitario de Elche, Alicante. · Medical Oncology, Complejo Hospitalario Torrecárdenas de Almería, Almería. · Medical Oncology, Hospital Marqués de Valdecilla, Santander. · Medical Oncology, Hospital Universitario Son Espases, Palma de Mallorca. · Medical Oncology, Hospital Universitario La Princesa, Madrid. · Medical Oncology, Complejo Hospitalario Universitario Ourense, Ourense. · Medical Oncology, Hospital Universitario 12 de Octubre, Madrid. · Medical Oncology, Hospital General Universitario de Valencia, Valencia. · Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain. ·Medicine (Baltimore) · Pubmed #29384960.

ABSTRACT: The main objective of the study was to evaluate the efficacy and safety of dabrafenib alone or combined with trametinib for compassionate use in patients with metastatic melanoma.This retrospective, observational study involved 135 patients with unresectable stage IIIC or stage IV melanoma from an expanded-access program at 30 Spanish centers.Forty-eight patients received dabrafenib monotherapy and 87 received combination dabrafenib and trametinib; 4.4% and 95.6% of the patients had stage IIIC and IV melanoma, respectively. All patients showed BRAF mutations in their primary or metastatic lesions; 3 were positive for V600K while the remainder had V600E or V600+. A positive response to treatment was reported in 89.3% of the patients. Overall survival rates at 12 and 24 months were 59.6% (95% confidence interval [CI], 52.5-68.9%) and 36.4% (95% CI, 27.8-45%), respectively. Progression-free survival rates at 12 and 24 months were 39.3% (95% CI, 31.1-47.5%) and 21.6% (95% CI, 14.5-28.7%), respectively. Fifty-seven patients (42.2%) reported cutaneous toxicity of any type, mainly hyperkeratosis (14.8%) and rash (11.9%). The most frequent adverse events were pyrexia (27.4%), asthenia (19.3%), arthralgia (16.9%), and diarrhoea (13.2%).Our results suggest that both dabrafenib alone or in combination with trametinib are effective for compassionate use in terms of response and/or survival rates. However, differences in patients' prognostic features ought to be considered. No new findings were revealed regarding the safety profiles of either regimen. This is the first study to evaluate the efficacy of these 2 selective BRAF and mitogen-activated extracellular signal-regulated kinase inhibitors in a real-world setting in Spain.

5 Article Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin. 2017

Agudo-López, Alba / Prieto-García, Elena / Alemán, José / Pérez, Carlos / Díaz-García, C Vanesa / Parrilla-Rubio, Lucía / Cabrera, Silvia / Navarro-Ranninger, Carmen / Cortés-Funes, Hernán / López-Martín, José A / Agulló-Ortuño, M Teresa. ·Laboratory of Translational Oncology, Instituto de Investigación Sanitaria Hospital 12 de Octubre (i + 12), Avda de Córdoba S/N, 28041, Madrid, Spain. · Organic Chemistry Department (Module 1), Universidad Autónoma de Madrid, C/Fco Tomás y Valiente, 5. Cantoblanco, 28049, Madrid, Spain. · Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda de Córdoba S/N, 28041, Madrid, Spain. · Inorganic Chemistry Department (Module 7), Universidad Autónoma de Madrid, C/Fco Tomás y Valiente, 5, Cantoblanco, 28049, Madrid, Spain. · Laboratory of Translational Oncology, Instituto de Investigación Sanitaria Hospital 12 de Octubre (i + 12), Avda de Córdoba S/N, 28041, Madrid, Spain. agullo@h12o.es. ·Mol Cancer · Pubmed #28231799.

ABSTRACT: BACKGROUND: Cisplatin is a potent antitumor agent. However, toxicity and primary and secondary resistance are major limitations of cisplatin-based chemotherapy, leading to therapeutic failure. We have previously reported that mono-sulfonamide platinum complexes have good antitumor activity against different tumoral cell lines and with a different and better cytotoxic profile than cisplatin. Besides, N-sulfonamides have been used extensively in medicinal chemistry as bactericides, anticonvulsant, inhibitors of the carbonic anhydrase, inhibitors of histone deacetylases, and inhibitors of microtubule polymerization, among others. METHODS: We aimed to compare the cytotoxic effects of cisplatin and a trans-sulfonamide-platinum-complex (TSPC), in two human melanoma cell lines that differ in their TP53 status: SK-MEL-5, TP53 wild type, and SK-MEL-28, TP53 mutated. We performed cytotoxicity assays with both drugs, alone and in combination, cell cycle analyses, western blotting and immunoprecipitation, and fluorescence immunocytochemistry. RESULTS: TSPC had similar antiproliferative activity than cisplatin against SK-MEL-5 (3.24 ± 1.08 vs 2.89 ± 1.12 μM) and higher against SK-MEL-28 cells (5.83 ± 1.06 vs 10.17 ± 1.29 μM). Combination of both drugs inhibited proliferation in both cell lines, being especially important in SK-MEL-28, and showing a synergistic effect. In contrast to cisplatin, TSPC caused G1 instead G2/M arrest in both cell lines. Our present findings indicate that the G1 arrest is associated with the induction of CDKN1A and CDKN1B proteins, and that this response is also present in melanoma cells containing TP53 mutated. Also, strong accumulation of CDKN1A and CDKN1B in cells nuclei was seen upon TSPC treatment in both cell lines. CONCLUSIONS: Overall, these findings provide a new promising TSPC compound with in vitro antitumor activity against melanoma cell lines, and with a different mechanism of action from that of cisplatin. Besides, TSPC synergism with cisplatin facilitates its potential use for co-treatment to reduce toxicity and resistance against cisplatin. TSPC remains a promising lead compound for the generation of novel antineoplastic agent and to explore its synergism with other DNA damaging agents.

6 Article Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program. 2014

Berrocal, Alfonso / Arance, Ana / Lopez Martin, Jose Antonio / Soriano, Virtudes / Muñoz, Eva / Alonso, Lorenzo / Espinosa, Enrique / Lopez Criado, Pilar / Valdivia, Javier / Martin Algarra, Salvador / Anonymous380801. ·aMedical Oncology, Hospital General Valencia bMedical Oncology, Instituto Valenciano de Oncologia, Valencia cMedical Oncology, Hospital Clinic i Provincial dMedical Oncology, Hospital Vall d´Hebron, Barcelona eMedical Oncology, Hospital 12 de Octubre fMedical Oncology, Hospital La Paz gMedical Oncology, Hospital MD Anderson Cancer Center, Madrid hMedical Oncology, Hospital ClinicoVirgen de la Victoria, Malaga iMedical Oncology, Hospital Virgen de las Nieves, Granada jMedical Oncology, Clinica Universitaria de Navarra, Pamplona, Spain. ·Melanoma Res · Pubmed #25046550.

ABSTRACT: Ipilimumab, a fully human, recombinant, monoclonal antibody to cytotoxic T-lymphocyte antigen 4 improves overall survival (OS) in previously treated and untreated metastatic melanoma. This retrospective analysis reports data gathered by a questionnaire on the demographics, outcomes, and toxicity of ipilimumab administered through an Expanded Access Program (EAP). Ipilimumab 3 mg/kg was administered intravenously every 3 weeks for four cycles to adults with metastatic melanoma. Efficacy outcomes included complete response, partial response (PR), progressive disease, stabilized disease, and OS. EAP data were collected from EAP physicians. A subgroup analysis examined efficacy in elderly patients (≥70 years) and factors predictive of survival were identified. Of 355 requests for ipilimumab, resulting in 288 treatments, completed questionnaires were received for 153 ipilimumab recipients (median age 58 years, 57.2% men). Efficacy was evaluated in 144 patients: complete response in 1.3%, PR in 9.6%, PR with previous progression 8.4%, stabilized disease in 14.5%, and progressive disease in 66.2%. The median OS was 6.5 months (199 days); 1-year survival was 32.9%. Predictive survival factors included lymphocytes over 1000/ml (P=0.0008) and lactate dehydrogenase more than 1.5×upper limit of normal (P=0.003). Cutaneous, hepatic, and gastrointestinal toxicities were mild. In 30 patients aged more than 70 years, ipilimumab efficacy and tolerability was similar to that of the overall population. In the clinical practice setting, ipilimumab is effective and well tolerated in patients with advanced melanoma, including elderly patients, when administered at the recommended dosage. Ipilimumab improves treatment options for patients who, until recently, have had little hope of an improved prognosis.